Table 1.
Baseline Characteristics of Subjects
| Characteristics | ||||
|---|---|---|---|---|
| LPV/r BID (n=159) |
LPV/r QD (n=161) |
Total (n=320) |
||
| Sex | Male | 122 (77%) | 127 (79%) | 249 (78%) |
| Female | 37 (23%) | 34 (21%) | 71 (22%) | |
| Age (yrs) | Mean (SD) | 38.2 (9.4) | 39.3 (10.4) | 38.8 (9.9) |
| Median (Q1, Q3) | 39.0 (31.0, 45.0) | 38.0 (32.0, 45.0) | 39.0 (31.5, 45.0) | |
| Min, Max | 17.0, 64.0 | 18.0, 66.0 | 17.0, 66.0 | |
| Race/ethnicity | White Non-Hispanic | 43 (27%) | 54 (34%) | 97 (30%) |
| Black Non-Hispanic | 58 (36%) | 51 (32%) | 109 (34%) | |
| Hispanic (Regardless of Race) |
51 (32%) | 54 (34%) | 105 (33%) | |
| Asian, Pacific Islander | 5 (3%) | 1 (1%) | 6 (2%) | |
| American Indian, Alaskan Native |
1 (1%) | 1 (1%) | 2 (1%) | |
| Other/unknown/more than one race |
1 (1%) | 0 (0%) | 1 (0%) | |
| IV drug history | Never | 137 (86%) | 143 (89%) | 280 (88%) |
| Currently | 0 (0%) | 1 (1%) | 1 (0%) | |
| Previously | 22 (14%) | 17 (11%) | 39 (12%) | |
| NRTI Started | Never started Rx | 1 (1%) | 0 (0%) | 1 (0%) |
| d4T XR | 95 (60%) | 100 (62%) | 195 (61%) | |
| TDF | 63 (40%) | 61 (38%) | 124 (39%) | |
|
History of AIDS Defining Diagnosis |
Yes | 26 (16%) | 32 (20%) | 58 (18%) |
| No | 133 (84%) | 129 (80%) | 262 (82%) | |
| Hepatitis C antibody | Positive | 20 (13%) | 21 (13%) | 41 (13%) |
| Negative | 136 (87%) | 138 (86%) | 274 (87%) | |
| Indeterminate | 0 (0%) | 1 (1%) | 1 (0%) | |
|
HIV-1 RNA (log10(cp/mL))* |
Mean (SD) | 4.9 (0.7) | 4.8 (0.6) | 4.9 (0.6) |
| Median (Q1, Q3) | 4.8 (4.5, 5.4) | 4.8 (4.5, 5.2) | 4.8 (4.5, 5.3) | |
| Min, Max | 3.0, 6.5 | 3.1, 6.6 | 3.0, 6.6 | |
| Screening HIV-1 RNA | < 100,000 | 77 (48%) | 79 (49%) | 156 (49%) |
| >= 100,000 | 82 (52%) | 82 (51%) | 164 (51%) | |
| CD4 Count (cells/mm3)* | Mean (SD) | 221 (187) | 233 (179) | 227 (183) |
| Median (Q1, Q3) | 194 (65.5, 314) | 218 (76.0, 336) | 203 (67.8, 321) | |
| Min, Max | 0.0, 890 | 0.0, 869 | 0.0, 890 | |
| (cells/mm3) | 0-50 | 33 (21%) | 35 (22%) | 68 (21%) |
| 51-100 | 18 (11%) | 14 (9%) | 32 (10%) | |
| 101-200 | 34 (21%) | 25 (16%) | 59 (18%) | |
| 201-350 | 45 (28%) | 51 (32%) | 96 (30%) | |
| 351-500 | 17 (11%) | 24 (15%) | 41 (13%) | |
| >500 | 12 (8%) | 12 (7%) | 24 (8%) | |
*
Baseline HIV RNA level and CD4 cell count were calculated as the geometric and arithmetic means, respectively, of pre-entry and entry evaluations.